Your browser is no longer supported. Please, upgrade your browser.
CTMX CytomX Therapeutics, Inc. daily Stock Chart
CTMX [NASD]
CytomX Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own0.20% Shs Outstand45.72M Perf Week1.37%
Market Cap396.67M Forward P/E- EPS next Y-2.81 Insider Trans-27.89% Shs Float41.01M Perf Month7.50%
Income-75.90M PEG- EPS next Q0.05 Inst Own80.50% Short Float4.10% Perf Quarter-0.53%
Sales77.60M P/S5.11 EPS this Y-11.10% Inst Trans0.18% Short Ratio2.44 Perf Half Y5.51%
Book/sh1.53 P/B5.57 EPS next Y-165.10% ROA-19.50% Target Price14.30 Perf Year-27.69%
Cash/sh5.33 P/C1.60 EPS next 5Y-0.90% ROE-99.70% 52W Range3.60 - 15.44 Perf YTD2.59%
Dividend- P/FCF- EPS past 5Y-17.70% ROI-216.20% 52W High-44.79% Beta0.69
Dividend %- Quick Ratio3.80 Sales past 5Y62.50% Gross Margin- 52W Low137.13% ATR0.44
Employees158 Current Ratio3.80 Sales Q/Q68.10% Oper. Margin- RSI (14)40.66 Volatility4.84% 5.59%
OptionableYes Debt/Eq0.00 EPS Q/Q185.30% Profit Margin-97.80% Rel Volume0.59 Prev Close8.31
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume689.39K Price8.52
Recom2.10 SMA202.66% SMA50-9.15% SMA20010.85% Volume404,735 Change2.59%
Jun-01-20Downgrade Jefferies Buy → Hold $16 → $10
May-14-20Reiterated H.C. Wainwright Buy $16 → $12
Mar-24-20Upgrade Wedbush Neutral → Outperform
Mar-04-20Initiated Barclays Equal Weight $7
Nov-20-19Initiated Guggenheim Buy
Nov-11-19Downgrade Wedbush Outperform → Neutral $25 → $8
Jun-13-19Initiated Mizuho Buy
May-14-19Initiated Cantor Fitzgerald Overweight $21
Mar-11-19Initiated Barclays Overweight $16
Nov-26-18Initiated Piper Jaffray Overweight $22
Oct-15-18Initiated Goldman Neutral $21
Sep-13-18Initiated H.C. Wainwright Buy $32
Jun-01-18Initiated SunTrust Buy $38
Jan-05-18Initiated Citigroup Buy $40
Sep-08-17Initiated Wedbush Outperform $26
Mar-27-17Initiated H.C. Wainwright Buy $24
Mar-02-17Initiated Instinet Buy $21
Jan-03-17Downgrade Oppenheimer Outperform → Perform
Nov-02-15Initiated Oppenheimer Outperform $17
Nov-02-15Initiated Jefferies Buy $19
Jul-10-20 05:30PM  
01:30PM  
01:00PM  
11:34AM  
Jul-09-20 04:20PM  
03:15PM  
Jul-08-20 06:50PM  
01:50PM  
01:15PM  
01:10PM  
Jul-07-20 05:30PM  
04:51PM  
Jul-06-20 11:00PM  
09:10PM  
01:40PM  
12:58PM  
01:30AM  
Jul-03-20 02:55PM  
11:19AM  
Jul-02-20 10:10PM  
09:40PM  
04:45PM  
03:24PM  
Jul-01-20 07:20PM  
06:32PM  
03:30PM  
03:00PM  
11:00AM  
10:18AM  
Jun-30-20 09:30PM  
08:20PM  
01:40PM  
01:00PM  
Jun-29-20 01:25PM  
10:59AM  
08:45AM  
07:45AM  
01:30AM  
Jun-27-20 09:24AM  
Jun-26-20 05:20PM  
04:38PM  
03:30PM  
02:45PM  
12:00PM  
11:43AM  
10:45AM  
Jun-24-20 07:00PM  
06:09PM  
05:30PM  
05:00PM  
Jun-23-20 07:20PM  
06:50PM  
01:40PM  
12:47PM  
Jun-22-20 07:45PM  
06:55PM  
06:50PM  
02:45PM  
02:30PM  
01:54PM  
09:00AM  
01:20AM  
Jun-20-20 06:57PM  
Jun-19-20 05:15PM  
04:20PM  
10:03AM  
Jun-18-20 11:30AM  
Jun-17-20 06:35PM  
04:00PM  
02:55PM  
01:00PM  
12:05PM  
Jun-16-20 05:50PM  
12:23PM  
08:15AM  
Jun-15-20 02:25PM  
Jun-12-20 10:10AM  
Jun-11-20 03:19PM  
02:29PM  
01:03PM  
12:00PM  
Jun-10-20 09:55PM  
09:05PM  
05:07PM  
04:00PM  
03:10PM  
02:10PM  
Jun-09-20 03:30PM  
02:50PM  
01:30PM  
01:02PM  
Jun-08-20 07:53PM  
06:57PM  
06:10PM  
05:10PM  
07:45AM  
06:20AM  
Jun-07-20 12:00PM  
Jun-06-20 10:51PM  
Jun-05-20 03:35PM  
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.President and CEOMay 12Option Exercise1.1336,00040,820120,306May 14 04:31 PM
McCarthy Sean A.President and CEOMay 12Sale15.0036,000540,00084,306May 14 04:31 PM